Incyte (INCY) Revenue & Revenue Breakdown
Incyte Revenue Highlights
Latest Revenue (Y)
$3.70B
Latest Revenue (Q)
$962.99M
Main Segment (Y)
Product
Main Geography (Y)
UNITED STATES
Incyte Revenue by Period
Incyte Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $3.70B | 8.87% |
| 2022-12-31 | $3.39B | 13.67% |
| 2021-12-31 | $2.99B | 11.98% |
| 2020-12-31 | $2.67B | 23.53% |
| 2019-12-31 | $2.16B | 14.71% |
| 2018-12-31 | $1.88B | 22.50% |
| 2017-12-31 | $1.54B | 38.93% |
| 2016-12-31 | $1.11B | 46.70% |
| 2015-12-31 | $753.75M | 47.36% |
| 2014-12-31 | $511.50M | 44.10% |
| 2013-12-31 | $354.95M | 19.49% |
| 2012-12-31 | $297.06M | 214.50% |
| 2011-12-31 | $94.45M | -44.40% |
| 2010-12-31 | $169.88M | 1733.55% |
| 2009-12-31 | $9.27M | 136.41% |
| 2008-12-31 | $3.92M | -88.62% |
| 2007-12-31 | $34.44M | 24.59% |
| 2006-12-31 | $27.64M | 252.32% |
| 2005-12-31 | $7.85M | -44.54% |
| 2004-12-31 | $14.15M | -69.96% |
| 2003-12-31 | $47.09M | -53.66% |
| 2002-12-31 | $101.61M | -53.66% |
| 2001-12-31 | $219.26M | 12.92% |
| 2000-12-31 | $194.17M | 23.67% |
| 1999-12-31 | $157.00M | 16.47% |
| 1998-12-31 | $134.80M | 52.49% |
| 1997-12-31 | $88.40M | 111.48% |
| 1996-12-31 | $41.80M | 242.62% |
| 1995-12-31 | $12.20M | 6000.00% |
| 1994-12-31 | $200.00K | -33.33% |
| 1993-12-31 | $300.00K | - |
Incyte generated $3.70B in revenue during NA 2023, up 8.87% compared to the previous quarter, and up 196.38% compared to the same period a year ago.
Incyte Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $962.99M | -7.74% |
| 2024-06-30 | $1.04B | 18.49% |
| 2024-03-31 | $880.89M | -13.07% |
| 2023-12-31 | $1.01B | 10.26% |
| 2023-09-30 | $919.02M | -3.73% |
| 2023-06-30 | $954.61M | 18.05% |
| 2023-03-31 | $808.67M | -12.74% |
| 2022-12-31 | $926.70M | 12.56% |
| 2022-09-30 | $823.30M | -9.67% |
| 2022-06-30 | $911.40M | 24.30% |
| 2022-03-31 | $733.24M | -15.02% |
| 2021-12-31 | $862.85M | 6.13% |
| 2021-09-30 | $812.99M | 15.20% |
| 2021-06-30 | $705.71M | 16.70% |
| 2021-03-31 | $604.72M | -23.41% |
| 2020-12-31 | $789.51M | 27.21% |
| 2020-09-30 | $620.64M | -9.80% |
| 2020-06-30 | $688.04M | 21.03% |
| 2020-03-31 | $568.51M | -1.88% |
| 2019-12-31 | $579.39M | 5.04% |
| 2019-09-30 | $551.58M | 4.09% |
| 2019-06-30 | $529.93M | 6.44% |
| 2019-03-31 | $497.86M | -5.78% |
| 2018-12-31 | $528.40M | 17.51% |
| 2018-09-30 | $449.68M | -13.77% |
| 2018-06-30 | $521.52M | 36.42% |
| 2018-03-31 | $382.28M | -13.93% |
| 2017-12-31 | $444.16M | 16.41% |
| 2017-09-30 | $381.53M | 16.88% |
| 2017-06-30 | $326.44M | -15.01% |
| 2017-03-31 | $384.08M | 17.64% |
| 2016-12-31 | $326.50M | 21.16% |
| 2016-09-30 | $269.47M | 9.41% |
| 2016-06-30 | $246.29M | -6.52% |
| 2016-03-31 | $263.46M | 8.03% |
| 2015-12-31 | $243.88M | 29.99% |
| 2015-09-30 | $187.61M | 15.11% |
| 2015-06-30 | $162.98M | 2.33% |
| 2015-03-31 | $159.28M | 28.48% |
| 2014-12-31 | $123.97M | -37.43% |
| 2014-09-30 | $198.15M | 98.98% |
| 2014-06-30 | $99.58M | 10.90% |
| 2014-03-31 | $89.79M | -7.50% |
| 2013-12-31 | $97.07M | 14.04% |
| 2013-09-30 | $85.12M | -16.28% |
| 2013-06-30 | $101.67M | 43.05% |
| 2013-03-31 | $71.08M | -37.57% |
| 2012-12-31 | $113.85M | 88.20% |
| 2012-09-30 | $60.49M | -30.10% |
| 2012-06-30 | $86.54M | 139.21% |
| 2012-03-31 | $36.18M | 25.23% |
| 2011-12-31 | $28.89M | 72.15% |
| 2011-09-30 | $16.78M | -0.17% |
| 2011-06-30 | $16.81M | -47.42% |
| 2011-03-31 | $31.97M | -62.77% |
| 2010-12-31 | $85.87M | 408.95% |
| 2010-09-30 | $16.87M | -66.15% |
| 2010-06-30 | $49.85M | 188.33% |
| 2010-03-31 | $17.29M | 151.79% |
| 2009-12-31 | $6.87M | 631.20% |
| 2009-09-30 | $939.00K | 19.01% |
| 2009-06-30 | $789.00K | 17.59% |
| 2009-03-31 | $671.00K | -28.46% |
| 2008-12-31 | $938.00K | -11.59% |
| 2008-09-30 | $1.06M | 72.80% |
| 2008-06-30 | $614.00K | -53.02% |
| 2008-03-31 | $1.31M | - |
Incyte generated $962.99M in revenue during Q3 2024, up -7.74% compared to the previous quarter, and up 100.88% compared to the same period a year ago.
Incyte Revenue Breakdown
Incyte Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|---|
| Milestone And Contract Revenue | $165.00M | $205.00M | $77.50M | $180.00M | - |
| Olumiant Royalty | $134.55M | $110.92M | $80.42M | - | - |
| OPZELURA | $128.74M | $4.91M | - | - | - |
| Royalty | $482.74M | $392.97M | $306.34M | $234.78M | - |
| PEMAZYRE Royalty Revenues | $84.65M | - | - | - | - |
| Tabrecta Royalty Revenues | $15.41M | $4.14M | - | - | - |
| Milestone and contract revenues | $165.00M | $95.00M | - | - | - |
| J A K A F I | $2.74B | - | - | - | - |
| M I N J U V I | $19.65M | - | - | - | - |
| Product | $2.75B | $2.07B | $1.77B | $1.47B | - |
| I C L U S I G | $105.84M | $105.00M | $89.95M | - | - |
| Product revenues, net | - | $2.32B | - | - | - |
| ICLUSIG | - | $4.67M | - | - | - |
| JAKAVI Royalty Revenues | - | $337.99M | - | - | - |
| MINJUVI | - | $68.53M | - | - | - |
| OLUMIANT Royalty Revenues | - | $220.88M | - | - | - |
| PEMAZYRE | - | $109.39M | - | - | - |
| Product royalty revenues | - | $569.25M | - | - | - |
| TABRECTA Royalty Revenues | - | $10.39M | - | - | - |
| Jakavi Royalty Revenues | - | - | $277.90M | $225.91M | - |
| Pemazyre | - | - | $25.88M | - | - |
| Product And Service Other | - | - | - | - | $203.00K |
Incyte's latest annual revenue breakdown by segment (product or service), as of Dec 22: Product (40.46%), J A K A F I (40.37%), Royalty (7.11%), Milestone And Contract Revenue (2.43%), Milestone and contract revenues (2.43%), Olumiant Royalty (1.98%), OPZELURA (1.90%), I C L U S I G (1.56%), PEMAZYRE Royalty Revenues (1.25%), M I N J U V I (0.29%), and Tabrecta Royalty Revenues (0.23%).
Quarterly Revenue by Product
| Product/Service | Sep 24 | Jun 24 | Mar 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tabrecta Royalty Revenues | $5.93M | $5.30M | $5.23M | $2.75M | $2.48M | $2.05M | $2.00M | $1.44M | $706.00K | - | - | - | - | - | - | - | - | - | - | - |
| ZYNYZ | $694.00K | $651.00K | $467.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| PEMAZYRE Royalty Revenues | $21.07M | $21.14M | $18.22M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| OPZELURA | $139.27M | $121.69M | $85.72M | $91.84M | $80.23M | $56.55M | $38.14M | $16.56M | $12.75M | - | - | - | - | - | - | - | - | - | - | - |
| Olumiant Royalty | $34.80M | $31.70M | $30.59M | $86.57M | $36.05M | $32.26M | $31.00M | $28.65M | $25.83M | $25.45M | $23.60M | $21.64M | - | - | - | - | - | - | - | - |
| Milestone And Contract Revenue | $18.00M | - | $25.00M | $35.00M | $10.00M | $110.00M | - | $95.00M | - | $17.50M | - | - | - | - | - | - | - | - | - | - |
| M I N J U V I | $31.44M | $31.12M | $23.87M | $556.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| J A K A F I | $115.74M | $99.32M | $89.59M | $547.37M | $529.05M | $465.71M | $516.88M | $487.78M | $473.71M | $459.48M | $466.46M | $433.39M | - | - | - | - | - | - | - | - |
| I C L U S I G | $29.75M | $26.86M | $30.34M | $28.52M | $28.19M | $25.64M | $28.58M | $26.38M | $22.80M | $27.25M | $24.31M | $20.61M | - | - | - | - | - | - | - | - |
| ICLUSIG | - | - | $30.34M | $27.72M | $29.09M | $27.68M | $25.93M | $26.22M | $26.07M | $-77.69M | - | - | - | - | - | - | - | - | - | - |
| JAKAVI Royalty Revenues | - | - | $89.59M | $96.55M | $90.45M | $76.69M | $85.81M | $83.71M | $70.87M | $95.70M | - | - | - | - | - | - | - | - | - | - |
| Milestone and contract revenues | - | - | $25.00M | - | $5.00M | $50.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| OLUMIANT Royalty Revenues | - | - | $30.59M | $29.61M | $32.01M | $34.16M | $20.37M | $66.00M | - | - | - | - | - | - | - | - | - | - | - | - |
| PEMAZYRE | - | - | $17.68M | $18.94M | $21.57M | $22.48M | $23.41M | $18.98M | $18.03M | $60.47M | - | - | - | - | - | - | - | - | - | - |
| Product | - | - | $729.92M | $783.20M | $827.00M | $693.24M | $713.01M | $594.01M | $575.15M | $504.81M | $559.47M | $522.25M | $500.29M | $486.73M | $490.78M | $454.00M | - | - | - | - |
| Royalty | - | - | $125.97M | $130.83M | $127.61M | $115.44M | $110.29M | $183.97M | $120.56M | $99.91M | $120.04M | $98.39M | $92.75M | $81.78M | $88.61M | $80.08M | - | - | - | - |
| TABRECTA Royalty Revenues | - | - | $5.23M | $4.14M | $4.80M | $4.18M | $4.11M | $3.58M | $3.48M | $3.12M | - | - | - | - | - | - | - | - | - | - |
| MINJUVI | - | - | - | $8.35M | $13.16M | $6.56M | $5.93M | $4.41M | $4.50M | $67.97M | - | - | - | - | - | - | - | - | - | - |
| JAKAFI | - | - | - | $636.25M | $682.38M | $579.97M | $647.49M | $619.60M | $597.67M | $544.46M | $592.37M | - | - | - | - | - | - | - | - | - |
| Product royalty revenues | - | - | - | - | - | - | - | - | $117.55M | $122.41M | $164.81M | - | - | - | - | - | - | - | - | - |
| Product revenues, net | - | - | - | - | - | - | - | - | $663.85M | $605.82M | $648.04M | - | - | - | - | - | - | - | - | - |
| Pemazyre | - | - | - | - | - | - | - | - | - | - | - | $17.56M | $17.91M | $13.46M | $14.01M | $8.09M | $3.79M | - | - | - |
| Jakavi Royalty Revenues | - | - | - | - | - | - | - | - | - | - | - | $94.66M | $82.04M | $65.60M | $87.05M | $68.31M | $66.22M | $56.33M | $65.01M | $58.44M |
| Milestone Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Incyte's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: OPZELURA (35.11%), J A K A F I (29.18%), Olumiant Royalty (8.77%), M I N J U V I (7.93%), I C L U S I G (7.50%), PEMAZYRE Royalty Revenues (5.31%), Milestone And Contract Revenue (4.54%), Tabrecta Royalty Revenues (1.49%), and ZYNYZ (0.17%).
Incyte Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|---|
| Europe | $147.00M | $124.10M | $105.00M | $90.00M | $79.90M |
| UNITED STATES | $3.20B | - | - | - | - |
| U.S. | - | $2.90B | - | - | - |
| U | - | - | $2.60B | $2.10B | $1.80B |
Incyte's latest annual revenue breakdown by geography, as of Dec 22: UNITED STATES (95.61%), and Europe (4.39%).
Quarterly Revenue by Country
| Country | Dec 19 | Dec 18 |
|---|---|---|
| Non Us | $88.60M | $69.20M |
Incyte's latest quarterly revenue breakdown by geography, as of Dec 19: Non Us (100.00%).
Incyte Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| INCY | Incyte | $3.70B | $962.99M |
| BGNE | BeiGene | $2.46B | $929.17M |
| BMRN | BioMarin Pharmaceutical | $2.42B | $733.87B |
| UTHR | United Therapeutics | $2.33B | $748.90M |
| ALNY | Alnylam Pharmaceuticals | $1.83B | $420.15M |
| SRPT | Sarepta Therapeutics | $1.24B | $413.46M |
| ARGX | argenx SE | $1.23B | $401.00M |
| IONS | Ionis Pharmaceuticals | $787.65M | $225.00M |
| ACAD | ACADIA Pharmaceuticals | $726.44M | $241.96M |
| HRMY | Harmony Biosciences | $582.02M | $186.04M |
| RARE | Ultragenyx Pharmaceutical | $434.25M | $147.03M |
| FOLD | Amicus Therapeutics | $399.36M | $110.40M |
| APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
| DNLI | Denali Therapeutics | $330.53M | - |
| AXSM | Axsome Therapeutics | $270.60M | $87.17M |
| ARWR | Arrowhead Pharmaceuticals | $240.74M | - |
| RXDX | Prometheus Biosciences | $6.81M | $1.10M |
INCY Revenue FAQ
What is Incyte’s yearly revenue?
Incyte's yearly revenue for 2023 was $3.7B, representing an increase of 8.87% compared to 2022. The company's yearly revenue for 2022 was $3.39B, representing an increase of 13.67% compared to 2021. INCY's yearly revenue for 2021 was $2.99B, representing an increase of 11.98% compared to 2020.
What is Incyte’s quarterly revenue?
Incyte's quarterly revenue for Q3 2024 was $962.99M, a -7.74% decrease from the previous quarter (Q2 2024), and a 4.78% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $1.04B, a 18.49% increase from the previous quarter (Q1 2024), and a 9.34% increase year-over-year (Q2 2023). INCY's quarterly revenue for Q1 2024 was $880.89M, a -13.07% decrease from the previous quarter (Q4 2023), and a 8.93% increase year-over-year (Q1 2023).
What is Incyte’s revenue growth rate?
Incyte's revenue growth rate for the last 3 years (2021-2023) was 23.75%, and for the last 5 years (2019-2023) was 71.19%.
What are Incyte’s revenue streams?
Incyte's revenue streams in c 22 are Milestone And Contract Revenue, Olumiant Royalty, OPZELURA, Royalty, PEMAZYRE Royalty Revenues, Tabrecta Royalty Revenues, Milestone and contract revenues, J A K A F I, M I N J U V I, Product, and I C L U S I G. Milestone And Contract Revenue generated $165M in revenue, accounting 2.43% of the company's total revenue, down -19.51% year-over-year. Olumiant Royalty generated $134.55M in revenue, accounting 1.98% of the company's total revenue, up 21.30% year-over-year. OPZELURA generated $128.74M in revenue, accounting 1.90% of the company's total revenue, up 2521.89% year-over-year. Royalty generated $482.74M in revenue, accounting 7.11% of the company's total revenue, up 22.84% year-over-year. PEMAZYRE Royalty Revenues generated $84.65M in revenue, accounting 1.25% of the company's total revenue Tabrecta Royalty Revenues generated $15.41M in revenue, accounting 0.23% of the company's total revenue, up 271.89% year-over-year. Milestone and contract revenues generated $165M in revenue, accounting 2.43% of the company's total revenue, up 73.68% year-over-year. J A K A F I generated $2.74B in revenue, accounting 40.37% of the company's total revenue M I N J U V I generated $19.65M in revenue, accounting 0.29% of the company's total revenue Product generated $2.75B in revenue, accounting 40.46% of the company's total revenue, up 32.78% year-over-year. I C L U S I G generated $105.84M in revenue, accounting 1.56% of the company's total revenue, up 0.80% year-over-year.
What is Incyte’s main source of revenue?
For the fiscal year ending Dec 22, the largest source of revenue of Incyte was Product. This segment made a revenue of $2.75B, representing 40.46% of the company's total revenue.